Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrim 1 study of intradermal tilsotolimod in high-risk cutaneous melanoma
NL-OMON60731Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2020
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in cutaneous melanoma (CM) comparing Tilsotolimod with Placebo (2 arms). Primary endpoint: Rate of tumor-positive sentinel lymph node. Started Jan 2020; status: active, not recruiting.
02
Drugs
tilsotolimod
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON60731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60731.